Naloxegol Oxalate(NKTR-118,MOVANTIK)|DC Chemicals

Naloxegol Oxalate(NKTR-118,MOVANTIK)|DC Chemicals

Naloxegol is the first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation.

Product Name: Naloxegol Oxalate(NKTR-118) |Catalog Number: DC8492 |CAS 1354744-91-4 |Other names: NKTR-118,NKTR118,NKTR 118 |Chemical Name: (5α,6α)-17-allyl-6-(2,5,8,11,14,17,20heptaoxadocosan-22-yloxy)-4,5-epoxymorphinan-3,14-diol oxalate |Molecule Formular: C34H53NO11.C2H2O4 |MW: 741.82

Naloxegol (NKTR-118) which is a novel PEGylated form of naloxol, a naloxone analog. Naloxegol has shown strong selectivity (more than 6000 folds) toward peripheral mu receptors and has been approved as first oral PAMORA for OIC due to use of opioids for non-cancer pain. PEGylation greatly restricts the activity of naloxegol to periphery. Naloxegol has been developed by Nektar Therapeutics and is marketed by AstraZeneca under the brand name MOVANTIK and received US-FDA approval on 16 Aug 2014.

For research and scientific purpose only, not for human use.